Generation Bio Co. (GBIO)

Market Cap	36.04M -44.0%
Revenue (ttm)	15.27M -17.8%
Net Income	-62.63M
EPS	-9.34
Shares Out	6.75M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	551,924
Open	5.70
Previous Close	5.74
Day's Range	5.34 - 5.71
52-Week Range	3.00 - 8.40
Beta	2.01
Analysts	n/a
Price Target	n/a
Earnings Date	Mar 12, 2026

About GBIO

Generation Bio Co., a biotechnology company, discovers, develops, and commercializes redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells. It develops cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) T cells to selectively delivery, intracellular, and genetically precise mechanism of target engagement could unlock a series of high-value historically undruggable disease-driving genes in autoimmunity. The company was former...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jun 12, 2020
• Employees: 115
• Stock Exchange: NASDAQ
• Ticker Symbol: GBIO
• Website: https://generationbio.com

Financial Performance

In 2024, Generation Bio Co.'s revenue was $19.89 million, an increase of 236.92% compared to the previous year's $5.90 million. Losses were -$131.67 million, 3.99% more than in 2023.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Jan 1, 2000

Data Sources Report a data error